CD36 and lung carcinoma: used a CD14+CD36+PANK+ macrophage-lung cancer fusion hybrid signature, developed through a combination of FACS isolation and RNA-seq, to assess whether macrophage-cancer cell fusion hybrids could be found in peripheral blood of patients with lung cancer (10).